Posted in Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma April 13, 2026 Pharmaceutical Technology The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy. RegulatoryOncologyRead full story